지엘팜텍

204840KOSDAQ

59.3 / 100

Reference Date: 2026-09-08

Financial Score13.0 / 40

News Sentiment21.3 / 25

Momentum15.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Surged 603.9% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

GELPAMTEK primarily operates in pharmaceutical R&D services and has expanded into drug distribution and marketing. Its subsidiary, GELPHARMA, focuses on pharmaceutical manufacturing and sales, with key products including gastritis treatments, neuropathic pain medications, and specialty drugs. The company also generates revenue through technology fees and royalties from licensing its improved new drug technologies.

Number of Employees

32people

Average Salary

46.5M KRW

Score Calculation Basis

Detailed Financial Score

PER

7115.85Industry Average 15.000.0Point

474.4x industry avg (risky)

PBR

4.46Industry Average 1.200.0Point

3.7x industry avg (risky)

ROE

0.06Industry Average 8.001.0Point

Well below industry avg

Debt Ratio

37.41Industry Average 100.006.5Point

Half of industry avg (excellent)

Trend 2023~20255.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲17.7% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲80.2% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -13.7% (improving, 3yr)

Detailed News Sentiment

4 totalPositive 4Neutral 0Negative 0Average Sentiment Score 85

Positive
지엘팜텍, 양성전립선비대증 치료제 ‘테라엘정’ 출시
지엘팜텍의 새로운 배뇨장애 치료제 출시로 인해 긍정적인 시장 반응 예상.
Positive
지엘팜텍, 상반기 매출 191억…전년比 18%↑
지엘팜텍의 상반기 매출이 전년 대비 18% 증가하며 실적 개선을 보여주었다.
Positive
지엘팜텍, 올해 상반기 흑자 지속…"매출 성장 탄력, 수익성 높일 것...
지엘팜텍의 상반기 매출이 전년 대비 약 18% 증가하며 흑자를 지속하고, 개량신약 중심의 포트폴리오 확장으로 수익성 개선이 기대된다.

Detailed Momentum

52-week position8.0Point

Near 52w high (100%, uptrend)

Current 5,730Won52-week high 5,73052-week low 780

1-month return6.0Point

1m +603.93% (strong rise)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0

Neutral투자판단관련주요경영사항(임상시험계획승인신청등결정) (W2505 경구제 제 3상 임상시험계획(IND) 승인)2026-08-21
Neutral반기보고서 (2026.06)2026-08-13
Neutral주권매매거래정지해제 (액면병합 주권 변경상장)2026-08-10